Cynata In Potential Japan Double As Fujifilm Acquires Lead Asset

Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.

Mesenchymal cell
Mesenchymal Cell Therapy Attracts Fujifilm • Source: Shutterstock

More from Deals

More from Business